Loading...
HomeMy WebLinkAbout2014-643 EMS - UNC Heart and Vascular Center - Data Use Agreement DATA USE AGREEMENT This data use agreement(the"Agreement"), effective as of the 15 th day of January,2014(the"Effective Date"),by and between Orange County EMS("Orange")and The University of North Carolina at Chapel Hill for its Heart and Vascular Center("Recipient"),establishes the terms and conditions under which Recipient will access and use certain data described below(the"Data"). Orange and Recipient are sometimes referred to in this Agreement singularly as a"Party"and collectively as the"Parties." WHEREAS, Recipient acknowledges that Orange is a"covered entity,"as such term is defined under the Administrative Simplification regulations codified at 45 C.F.R. Parts 160 and 164, promulgated pursuant to the Health Insurance Portability and Accountability Act of 1996, as amended(collectively, "HIPAA"), and as such, is required to protect the privacy of Protected Health Information, as that term is defined at 45 C.F.R. 160.103,maintained by covered entity; WHEREAS,pursuant to 45 C.F.R. § 164.512(i), Orange is permitted to disclose Protected Health Information to Recipient for research purposes,where Orange receives documentation that an Institutional Review Board("MM")of competent jurisdiction, or other privacy board as defined at 45 C.F.R. § 164.512(i)(1)(i)(B),has approved an alteration to or waiver of the authorization otherwise required by 45 C.F.R. § 164.508; and WHEREAS,this Agreement is intended to meet the requirements of 45 C.F.R. § 164.512(i)and to otherwise secure adequate assurances from Recipient that Recipient will restrict use or disclosure of the Data received pursuant to this Agreement according to the terms and conditions herein; NOW THEREFORE, in consideration of the mutual promises and covenants herein, and for other good and valuable consideration,the receipt and sufficiency of which is hereby acknowledged,the Parties agree as follows: 1. Description of Data. Recipient may obtain from Orange specific clinical data from selected Orange EMS patients. Recipient acknowledges that Orange may provide Data to Recipient pursuant to a waiver of authorization granted by an IRB of competent jurisdiction or by a privacy board as defined at 45 C.F.R. § 164.512(i), in accordance with 45 C.F.R. § 164.512(i)("Waiver"). 2. Recipient's Use of Data. Except as otherwise specified herein, Orange grants Recipient the right to use and disclose the Data solely in fulfillment of its professional obligations for determining cause of sudden unexpected death, provided such use is consistent with the terms, conditions and purposes stated in the relevant Waiver. Recipient acknowledges and agrees that,prior to Orange's release of Data to Recipient,Recipient shall provide evidence of the Waiver and a copy of such Waiver shall be attached to this Agreement as Exhibit A. 3. Restrictions on Recipient's Use of Data. 3.1 Recipient agrees to comply with all applicable federal and state laws and regulations concerning the privacy and confidentiality of Protected Health Information and to use or disclose the Data exclusively for the purposes set forth in Section 2 above or as required by law. Without limiting the generality of the foregoing,Recipient agrees to use or disclose the Data solely as permitted by the Waiver. 3.2 Recipient agrees to use appropriate safeguards to protect the Data from misuse and unauthorized access or disclosure, including,without limitation,(i)maintaining adequate physical controls and password protections for any server or system on which the Data may reside; (ii)ensuring that Data is not stored on any mobile device(e.g. laptop, smartphone)or 1 transmitted electronically unless encrypted; and(iii)taking any other measures reasonably necessary to prevent any use or disclosure of the Data other than as provided in this Agreement. 3.3 Recipient will report to Orange any use or disclosure of the Data not provided for by this Agreement of which Recipient becomes aware. Such report shall be made to Orange at the address noted in Section 8 as soon as reasonably possible. Recipient will cooperate with any remediation that Orange reasonably determines is necessary to(i)address any applicable reporting requirements; and(ii)mitigate any effects of such unauthorized use or disclosure of the Data. 3.4 Recipient will ensure that any agents, including subcontractors,to whom it provides the Data agree to the same restrictions and conditions set forth in this Agreement. 4. License to Use Data for Research Purposes. This Agreement and the resulting transfer of Data constitute a license to Recipient to use the Data solely for the research purposes set forth in Section 2. Recipient agrees that nothing herein shall be deemed a grant of any intellectual property rights or other rights to use the Data for any products or processes for profit-making or commercial purposes. 5. Term and Termination. This Agreement shall be effective as of the Effective Date and shall remain in effect as long as Recipient retains the Data. Either Party may terminate this Agreement with or without cause upon thirty(30)days' written notice to the other Party. 6. Notice. Notice regarding termination or other matters relating to this Agreement shall be made in writing sent to the following individuals: If to Orange: Director Emergency Services Post Office Box 8181 Hillsborough,North Carolina 27278 (9J 9)245-6100 If to Recipient: Eugene Chung,M.D. 160 Dental Circle 6024 Burnette Womack Bldg Chapel Hill,NC 27599 7. Miscellaneous Provisions. 7.1 Entire Agreement. This Agreement contains all of the terms and conditions agreed upon by the Parties regarding the subject matter of this Agreement and supersedes any prior agreements, oral or written, and all other communications between the Parties relating to such matters. 7.2 Severability. If any provision of this Agreement is determined to be invalid, such determination shall not affect the validity of the remaining provisions. 7.3 Waiver.The waiver by any Party of any provision or breach of this Agreement shall not operate or be construed as a waiver of any other provision of subsequent breach. 7.4 Representation to Others. Recipient has no rights to use the names,trademarks or other symbols of Orange without prior written consent; provided,however,that Recipient may make factual statements regarding its receipt of the Data pursuant to this Agreement. 2 7.5 Amendments. This Agreement may be amended or modified only with mutual written consent of the Parties. 7.6 Governing Law. This Agreement shall be governed by the laws of the State of North Carolina. 7.7 Change in Law. The Parties agree to negotiate in good faith to amend this Agreement to comport with changes in law that materially alter either or both Parties' obligations under this Agreement, provided however,that if the Parties are unable to agree to mutually acceptable amendment(s)by the compliance date of the change in applicable law or regulations, either Party may immediately terminate this Agreement. 7.8 Relationship of the Parties. Nothing in this Agreement shall be construed to create a partnership,joint venture, agency, employment or other joint business relationship between the Parties or any of their affiliates. 7.9 No Third Party Beneficiaries. Nothing in this Agreement shall confer upon any person other than the Parties and their respective successors or assigns, any rights,remedies, obligations,or liabilities whatsoever. 7.10 Assignment. This Agreement is non-assignable and non-transferrable by Recipient without the prior written consent of Orange. Assignments made in violation of this provision are null and void. Recipient acknowledges and agrees that Orange retains the right to assign or delegate any of its rights or obligations hereunder to any of its affiliates or subsidiaries. 7.11 Authority. Each Party, and the person signing on its behalf,represents that it is authorized to enter into this Agreement and the Party is capable of performing its obligations under this Agreement. 7.12 Headings. The headings and other captions in this Agreement are for convenience and reference only and shall not be used in interpreting, construing or enforcing this Agreement. IN WITNESS WHEREOF,the Parties have executed this Agreement as of the day and year set forth below. ORANGE COUNTY EMS THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL By: By: Name (printed): Q_ 6� �� Ot/" Name(printed): Title: 0�S (rMQr-`Q` Title: K7W-- • Date: / 02 Date: 194 Address: 5 l� ��w�4 � 1b1 Address: (bl AC KY� 3 Exhibit A Copy of Waiver 1'111' UN1Vt'ItS1`1'Y ol' NORT11 CAROLINA 11 4 II A 1't• I If 1 1 1, April 11, 2013 Replaces letter dated 1/3/2013 and is revised to provide a more comprehensive study description and to clarify that research is limited to decedents. To: Eugene Chung Heart And Vascular Center From: Office of Human Research Ethics Date: 4/11/2013 RE: Determination that Research or Research-Like Activity does not require IRB Approval Study#: 12-0083 Study Title: NC Sudden Unexpected Cardiac Death Registry This submission was reviewed by the Office of Human Research Ethics, which has determined that this submission does not constitute human subjects research as defined under federal regulations [45 CFR 46.102 (d or f) and 21 CFR 56.102(c)(e)(1)] and does not require IRB approval. The use or disclosure of PHI is sought solely for research on PHI of decedents. If the IRB requests it, the researcher will provide documentation to the death of the individuals. Study Description: Background Sudden unexplained death (SUD), also known as sudden cardiac arrest(SCA) and sudden cardiac death (SCD) is the most common cause of death in the United States. Estimates of SUD in the US vary widely, from 180,000 to >450,000 annually. The mechanisms of SUD are poorly understood. Large population studies point to fatal cardiac arrhythmias as the culprit. Cohort studies of SUD victims confirm this view, but generally these studies have been done on homogeneous populations, largely consisting of Caucasians in Oregon and Europe. 4 I Objective We propose to collect data on SUD victims in North Carolina in order to determine t1-,le rate of sudden unexplained death by gender, race and socioeconomic class in NC. Further, vie will evaluate the collected data to develop a risk stratification tool in order to improve the screening process for patients at risk for sudden unexplained death. Methods Beginning March 1, 2013 all residents of Wake County North Carolina that undergo sudden unexplained death will be ascertained from emergency medical services,the medical examiner, and emergency rooms of area hospitals. A comprehensive evaluation will be performed, including analysis of circumstances of death, medical records, and available autopsy data. A DNA swab will be done on all candidates. An independent adjudication committee will determine if subjects meet study criteria for sudden unexplained death. An independent lab will perform DNA analysis. Annual incidence rates will be calculated for all residents and demographic subgroups; complete phenotyping will be done on all subjects. The program will be expanded to 36 other counties in North Carolina in the near future. If your study protocol changes in such a way that this determination will no longer apply, you should contact the above IRB before making the changes. CC: Irion Pursell, Heart and Vascular Center 5